In escalating legal skirmishes over the U.S pharmaceutical market’s diabetes sector, Sanofi-Aventis U.S. is pressing a Pennsylvania federal court to discard allegations put forth by Mylan Pharmaceuticals. The claims by Mylan insist that Sanofi utilized unlawful discounts and patent litigation to effectively inhibit the entry of Mylan’s generic version of injectable insulin into the marketplace.
Sanofi’s contention is that Mylan’s antitrust complaint is composed of a confusing confluence of accusations, which it characterizes as a “mishmash” or a disorderly mixture. They further argue that the assertions made by Mylan do not meet the pleading requirements demanded in Sherman Act lawsuits.
The Sherman Act, an antitrust statute passed by Congress in 1890, prohibits certain business activities that it defines as ‘unfair’ in a market setting. It also mandates the federal government to investigate and pursue trusts, companies, and organizations suspected of violating the Act.
Undoubtedly, the manner in which the court handles these claims might have significant implications for the pharmaceutical sector, particularly concerning antitrust disputes. It continues to serve as a litmus test for the standards required when making accusations related to the venerable Sherman Act.
If you’re interested in staying updated about this matter, further information can be obtained by following the case developments at Law360.